Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pieris Pharma (PIRS)

Pieris Pharma (PIRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 384,255
  • Shares Outstanding, K 66,711
  • Annual Sales, $ 29,320 K
  • Annual Income, $ -37,230 K
  • 60-Month Beta 1.19
  • Price/Sales 12.65
  • Price/Cash Flow N/A
  • Price/Book 7.17
Trade PIRS with:

Options Overview

Details
  • Implied Volatility 114.06%
  • Historical Volatility 59.93%
  • IV Percentile 16%
  • IV Rank 20.33%
  • IV High 346.14% on 09/25/20
  • IV Low 54.83% on 03/24/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 1,137
  • Volume Avg (30-Day) 1,009
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 12,391
  • Open Int (30-Day) 14,252

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.24
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.35
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.68 +56.52%
on 08/17/21
6.06 -4.95%
on 09/09/21
+2.00 (+53.19%)
since 08/16/21
3-Month
3.21 +79.44%
on 07/27/21
6.06 -4.95%
on 09/09/21
+2.29 (+65.99%)
since 06/16/21
52-Week
1.70 +238.82%
on 05/05/21
6.06 -4.95%
on 09/09/21
+2.88 (+100.00%)
since 09/16/20

Most Recent Stories

More News
Pieris Pharmaceuticals Inc.: The Winning Streak Continues (PIRS)

(MENAFN - Investor Brand Network) Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) traded at a new 52-week high today of $5.82. This new high was reached on above average trading volume as 29.7 million shares...

PIRS : 5.76 (+3.60%)
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.76 (+3.60%)
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.76 (+3.60%)
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Misses Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -25.00% and -61.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

PIRS : 5.76 (+3.60%)
Pieris Pharmaceuticals: Q2 Earnings Snapshot

BOSTON (AP) _ Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $15.9 million in its second quarter.

PIRS : 5.76 (+3.60%)
Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

PIRS : 5.76 (+3.60%)
Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team

Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical OfficerShane Olwill, Ph.D., promoted to Chief Development Officer

PIRS : 5.76 (+3.60%)
Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021

BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 5.76 (+3.60%)
Thinking about buying stock in Pieris Pharmaceuticals, Paysafe, Tonix Pharmaceuticals, FibroGen, or Arbutus Biopharma?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, PSFE, TNXP, FGEN, and ABUS.

ABUS : 4.31 (+2.13%)
FGEN : 11.72 (+0.17%)
TNXP : 0.6305 (+1.60%)
PIRS : 5.76 (+3.60%)
PSFE : 8.25 (-0.84%)
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosisGrant to...

PIRS : 5.76 (+3.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

See More

Key Turning Points

3rd Resistance Point 6.23
2nd Resistance Point 6.03
1st Resistance Point 5.90
Last Price 5.76
1st Support Level 5.57
2nd Support Level 5.37
3rd Support Level 5.24

See More

52-Week High 6.06
Last Price 5.76
Fibonacci 61.8% 4.39
Fibonacci 50% 3.88
Fibonacci 38.2% 3.37
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar